Legal & General Group Plc Has $43.64 Million Stock Holdings in Solventum Corporation $SOLV

Legal & General Group Plc grew its holdings in Solventum Corporation (NYSE:SOLV) by 3.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 550,766 shares of the company’s stock after buying an additional 18,268 shares during the quarter. Legal & General Group Plc owned approximately 0.32% of Solventum worth $43,643,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. LSV Asset Management increased its position in Solventum by 364.5% in the third quarter. LSV Asset Management now owns 35,122 shares of the company’s stock worth $2,564,000 after purchasing an additional 27,561 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. increased its position in Solventum by 15.3% in the third quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 307,789 shares of the company’s stock worth $22,469,000 after purchasing an additional 40,812 shares during the period. Davis Selected Advisers increased its position in Solventum by 0.5% in the third quarter. Davis Selected Advisers now owns 5,517,611 shares of the company’s stock worth $402,786,000 after purchasing an additional 24,950 shares during the period. Appleton Partners Inc. MA acquired a new stake in Solventum in the fourth quarter worth about $7,008,000. Finally, SG Americas Securities LLC increased its position in Solventum by 92.3% in the fourth quarter. SG Americas Securities LLC now owns 93,681 shares of the company’s stock worth $7,423,000 after purchasing an additional 44,970 shares during the period.

Wall Street Analyst Weigh In

A number of analysts recently commented on the company. Piper Sandler lowered their price objective on Solventum from $98.00 to $92.00 and set an “overweight” rating for the company in a research report on Friday, April 17th. Wells Fargo & Company lowered their price objective on Solventum from $83.00 to $70.00 and set an “equal weight” rating for the company in a research report on Wednesday, May 6th. BTIG Research reiterated a “buy” rating and issued a $89.00 price objective on shares of Solventum in a research report on Wednesday, May 6th. Wall Street Zen cut Solventum from a “buy” rating to a “hold” rating in a report on Sunday, March 8th. Finally, Rothschild & Co Redburn began coverage on Solventum in a report on Tuesday, March 24th. They set a “sell” rating and a $60.00 target price on the stock. Eight research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $84.25.

Solventum Trading Down 1.1%

NYSE:SOLV opened at $75.13 on Friday. Solventum Corporation has a fifty-two week low of $62.38 and a fifty-two week high of $88.20. The company has a debt-to-equity ratio of 0.96, a current ratio of 1.07 and a quick ratio of 0.75. The stock has a market capitalization of $13.01 billion, a PE ratio of 9.21, a price-to-earnings-growth ratio of 1.16 and a beta of 0.59. The business’s 50-day simple moving average is $69.57 and its 200-day simple moving average is $75.04.

Solventum (NYSE:SOLV) last released its quarterly earnings data on Tuesday, May 5th. The company reported $1.48 earnings per share for the quarter, beating the consensus estimate of $1.35 by $0.13. Solventum had a return on equity of 23.51% and a net margin of 17.33%.The business had revenue of $2.01 billion for the quarter, compared to analysts’ expectations of $1.97 billion. During the same quarter in the previous year, the business posted $1.34 EPS. Solventum’s revenue for the quarter was down 3.0% on a year-over-year basis. Solventum has set its FY 2026 guidance at 6.600-6.600 EPS. Sell-side analysts expect that Solventum Corporation will post 6.58 earnings per share for the current fiscal year.

Insider Buying and Selling at Solventum

In other Solventum news, Director Amy Mcbride Wendell acquired 1,475 shares of the business’s stock in a transaction dated Tuesday, March 10th. The shares were acquired at an average price of $68.03 per share, for a total transaction of $100,344.25. Following the acquisition, the director directly owned 5,039 shares of the company’s stock, valued at approximately $342,803.17. This trade represents a 41.39% increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.24% of the stock is owned by company insiders.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.